Breaking News
Get 50% Off 0
Unlock Premium Data: Up to 50% Off InvestingPro CLAIM SALE
Close

Novartis AG (NOVN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
94.39 +0.06    +0.06%
- Delayed Data. Currency in CHF ( Disclaimer )
Type:  Equity
Market:  Switzerland
ISIN:  CH0012005267 
VALOR:  1200526
  • Volume: 4,509,282
  • Bid/Ask: 94.38 / 94.40
  • Day's Range: 94.02 - 94.81
Novartis 94.39 +0.06 +0.06%

NOVN Income Statement

 
Featured here, the Income Statement (earnings report) for Novartis AG, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
AnnualQuarterly
Advanced Income Statement
Period Ending: 2024
31/03
2023
31/12
2023
30/09
2023
30/06
Total Revenue 12120 11776 12092 13936
Revenue 11829 11423 11782 13622
Other Revenue, Total 291 353 310 314
Cost of Revenue, Total 3091 2987 3089 4006
Gross Profit 9029 8789 9003 9930
Total Operating Expenses 8390 8789 8642 10239
Selling/General/Admin. Expenses, Total 2840 3444 3093 3673
Research & Development 2237 2275 2356 2394
Depreciation / Amortization 218 192 238 270
Interest Expense (Income) - Net Operating -221 -217 -222 -224
Unusual Expense (Income) - - - -
Other Operating Expenses, Total 225 108 88 120
Operating Income 3730 2987 3450 3697
Interest Income (Expense), Net Non-Operating - - - -
Gain (Loss) on Sale of Assets -16 -33 96 -23
Other, Net 617 643 1802 951
Net Income Before Taxes 3129 2377 1552 2769
Provision for Income Taxes 441 -261 39 452
Net Income After Taxes 2688 2638 1513 2317
Minority Interest 81 83 81 84
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items 2688 2638 1511 2316
Total Extraordinary Items - 5842 250 -
Net Income 2688 8480 1761 2316
Total Adjustments to Net Income - -5842 -250 -
Income Available to Common Excluding Extraordinary Items 2688 2638 1511 2316
Dilution Adjustment -5.36 5840.14 246.25 -9.45
Diluted Net Income 2693.36 2639.86 1514.75 2325.45
Diluted Weighted Average Shares 2056 2065 2075 2095
Diluted EPS Excluding Extraordinary Items 1.31 1.28 0.73 1.11
DPS - Common Stock Primary Issue - 3.92 - -
Diluted Normalized EPS 1.09 0.878 0.984 1.07
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NOVN Comments

Write your thoughts about Novartis AG
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Pablo Germain
Pablo Germain Jan 10, 2023 1:48PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Could someone explain to me today's -2%?
Mr Ride
MrRide Jan 10, 2023 1:48PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Citi analyst downgraded Novartis (SW) (NVS) from Buy to Neutral with a price target of CHF86.00 (from CHF95.00).
Chemsedine Bendaci
Chemsedine Bendaci Feb 02, 2022 2:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
great results coming
Chemsedine Bendaci
Chemsedine Bendaci Jan 12, 2022 6:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
price target 116.34 according to zone bourse
Michael Näf
Michael Näf Feb 24, 2021 6:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Now good price to go in!
Vima OG
Vima OG Feb 26, 2020 11:38AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Long term.
Kristof Mouton
Stoffel Sep 17, 2019 4:40PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
before investing in @novartis, read #teampia (twitter).
MoneyManager MoneyManager
Money2Manage4U Sep 17, 2019 4:40PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what refers ?
José Spescha
José Spescha Sep 17, 2019 4:40PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I can not open #teampia. What is the conclusion?
Toni Fluxá
Toni Fluxá Apr 10, 2019 8:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
botton at 81
Levo Goldberg
Levo Goldberg Apr 10, 2019 8:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hope so loaded heavily at 85....
Brunello Pianca
Brunello Pianca Jan 15, 2019 12:13PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
must hold 83.50 for uptrend to resume
Tomas Lysak DiS
Tomas Lysak DiS Aug 23, 2018 7:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
yes. Novartis is a good company with solid numbers.
Shadow Trader
ShadowTrader Sep 10, 2017 8:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nice time to buy ? I'm not pretty sure... any one can say something about. ?. thanks to all
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email